VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
1-Year Return
31.42%
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
64.25%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Edgewise Therapeutics
EWTX
$1.64B
| $128K | 0.03% |
+5,829
| New | +$128K |
|
377
Northern Oil and Gas
NOG
$2.42B
| $127K | 0.03% |
+4,214
| New | +$127K |
|
378
Berry Corp
BRY
$249M
| $127K | 0.03% |
39,551
-162,346
| -80% | -$521K |
|
379
Disc Medicine
IRON
$2.11B
| $127K | 0.03% |
+2,556
| New | +$127K |
|
380
Dianthus Therapeutics
DNTH
$853M
| $127K | 0.03% |
+6,986
| New | +$127K |
|
381
Scholar Rock
SRRK
$3.02B
| $127K | 0.03% |
+3,939
| New | +$127K |
|
382
SITE Centers
SITC
$490M
| $124K | 0.03% |
+9,696
| New | +$124K |
|
383
Recursion Pharmaceuticals
RXRX
$2.01B
| $124K | 0.03% |
+23,518
| New | +$124K |
|
384
AbCellera Biologics
ABCL
$1.26B
| $124K | 0.03% |
+55,645
| New | +$124K |
|
385
Apple Hospitality REIT
APLE
$3.09B
| $124K | 0.03% |
+9,603
| New | +$124K |
|
|
ITOS
386
DELISTED
iTeos Therapeutics
ITOS
| $123K | 0.03% |
+20,663
| New | +$123K |
|
387
Viridian Therapeutics
VRDN
$1.53B
| $123K | 0.03% |
+9,129
| New | +$123K |
|
388
Civitas Resources
CIVI
$3.19B
| $122K | 0.03% |
+3,500
| New | +$122K |
|
|
VERV
389
DELISTED
Verve Therapeutics
VERV
| $120K | 0.03% |
+26,348
| New | +$120K |
|
390
MoonLake Immunotherapeutics
MLTX
$3.77B
| $119K | 0.03% |
+3,050
| New | +$119K |
|
391
Allogene Therapeutics
ALLO
$255M
| $119K | 0.03% |
+81,270
| New | +$119K |
|
|
BCAX
392
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $119K | 0.03% |
+9,097
| New | +$119K |
|
393
Cogent Biosciences
COGT
$1.82B
| $118K | 0.03% |
+19,687
| New | +$118K |
|
394
ArriVent BioPharma
AVBP
$819M
| $117K | 0.03% |
+6,348
| New | +$117K |
|
|
AAT
395
American Assets Trust
AAT
$1.28B
| $116K | 0.03% |
+5,765
| New | +$116K |
|
396
uniQure
QURE
$985M
| $116K | 0.03% |
+10,906
| New | +$116K |
|
|
SLRN
397
DELISTED
ACELYRIN
SLRN
| $115K | 0.03% |
46,372
+10,672
| +30% | +$26.4K |
|
398
Beam Therapeutics
BEAM
$2.11B
| $114K | 0.03% |
+5,856
| New | +$114K |
|
399
Celldex Therapeutics
CLDX
$1.52B
| $113K | 0.03% |
+6,208
| New | +$113K |
|
400
EyePoint Pharmaceuticals
EYPT
$966M
| $112K | 0.03% |
+20,674
| New | +$112K |
|